Pfizer Inc. said Thursday the cancer drug Sutent did not meet key goals in two late-stage studies focusing on advanced breast cancer.

Pfizer Inc. said Thursday it discontinued a late-stage study of the drug candidate figitumumab in patients with late-stage lung cancer, citing a lack of effectiveness.

THURSDAY, March 11 (HealthDay News) -- The decrease in cancer deaths in the United States since 1990 is the result of reduced tobacco use, increased cancer screening and improvements in treatment, according to an American Cancer Society study.

A sticking-plaster approach to treating skin cancer has been unveiled at Ninewells Hospital in Dundee.

March 11 (Bloomberg) -- Pfizer Inc . said the cancer drug Sutent failed to halt the progression of advanced breast tumors in two studies, and the company stopped a trial of an experimental medicine to treat lung malignancy.

March 12 (Bloomberg) -- Scientists have uncovered how a drug used in blood cancer medicines leads to short or missing limbs in babies, moving closer to developing treatments without the risk of these birth defects.

Birth-control pills may lead to longer lives for women, according to a 40-year study that showed users were less likely to die of heart disease, cancer or a range of other medical ailments.

Pfizer ends study on potential lung cancer drug, committee says it won't meet treatment goal Pfizer - Lung cancer - Cancer - Health - Diseases & Conditions

Pfizer says Sutent fails to meet key goals in 2 late-stage breast cancer studies Cancer - Health - Conditions and Diseases - Sunitinib - Clinical trial

March 11 (Bloomberg) -- Pfizer Inc . said the cancer drug Sutent failed to meet its main goals in two late-stage studies of advanced breast tumors and the company stopped a late-stage trial of an experimental medicine for a type of lung malignancy.